NCT05838521View on ClinicalTrials.gov

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2028

Conditions

Cervical Cancer

Interventions

DRUG

Sacituzumab govitecan

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).

Trial Locations (1)

06520

RECRUITING

Smilow Cancer Hospital at Yale New Haven, New Haven

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Yale University

OTHER